JP Morgan Healthcare Conference
Telix Pharmaceuticals Acquires Early-Stage Assets From ImaginAb, Shares Late-Stage Pipeline Updates
Premium
The firm will pay $45 million upfront for several new targeted agents that it plans to pair with isotopes to develop both diagnostically and therapeutically.
JP Morgan Healthcare Conference, Day 3: iTeos, AbbVie, Lexeo Therapeutics, Grail
On the third day, drugmakers provided updates on precision medicines for cancer and Alzheimer's, and Grail talked about the launch of a new version of the Galleri test.
The firm is aiming to break even on its cash flow by 2027 by narrowing its focus on its sarcoma treatments and pipeline candidates with the greatest potential.
JP Morgan Healthcare Conference, Day 2: Novartis, Relay, Erasca, Syndax, AstraZeneca, and More
On the second day, Novartis boasted of Kisqali's $8 billion potential, Relay said it's taking a PI3Kα inhibitor into Phase III, and Syndax talked about Revuforj in NPM1-mutant AML.
Despite Leqembi's initial slow sales, the firm's CEO cited areas for the drug's growth and ambitions for an antisense oligonucleotide candidate targeting tau.